Back to 2015 Joint Annual Meeting

Introduction:
Few definitive and durable interventions exist for Peyronie's disease (PD) other than surgical repair. We reported the use of injectable Collagenase Clostridium histolyticum (CCh), a collagenolytic agent towards collagen for patients with PD.
Materials and Methods:
From May 2014-March 2015, we prospectively followed PD patients with > 30 degrees of penile curvature who received CCh from a single provider at a single institution. Patients’ PD symptoms across three domains: psychological and physical symptoms (scored 0-24), penile pain (0-30) and bother (0-18) were evaluated by the validated Peyronie’s Disease Questionnaire (PDQ). Objective measurements of penile curvature and deformity were also assessed.
Results:
We identified 31 unique PD patient treated with CCh. 20 had data available for analysis with 11 in active treatment. Mean follow-up was 168 days with an average of 4.8 injections performed per patient. Surveillance concluded for 3 patients, who completed treatment after achieving success following 2 injections. Mean pre-treatment penile curvature was 41 degrees. There was a significant curvature reduction of 15.5 degrees (p < 0.01) after therapy. There was an interval improvement in the psychological and physical symptoms (mean decrease 0.74, p < 0.01) and bother score (mean decrease 0.65, p < 0.01), but no significant improvement in penile pain (p = 0.45). One instance of a penile hematoma managed conservatively.
Conclusions:
In this prospective series, CCh injection is clinically effective and safe in patients with PD resulting in improvements of penile curvature, subjective bother, and psychological and physical symptoms.